US Stock Market Move | Q1 profit turned into a loss, Sarepta Therapeutics (SRPT.US) continues to fall nearly 20%, dropping 40% over 2 trading days.
On Wednesday, Sarepta Therapeutics (SRPT.US) continued to fall by nearly 20%, with a 40% drop in the past two trading days, trading at $37.27.
On Wednesday, Sarepta Therapeutics (SRPT.US) continued to fall by nearly 20%, with a 40% drop over the past two trading days, closing at $37.27. On the news front, the company reported a non-GAAP diluted loss of $3.42 per share for the first quarter, compared to a profit of $0.72 per share in the same period last year. Analysts surveyed by FactSet had expected a profit of $2.52 per share. Revenue increased from approximately $414 million in the same period last year to $745 million. Analysts surveyed by FactSet had expected revenue to be $688 million. The company revised its 2025 net product revenue guidance down to a range of $2.3 billion to $2.6 billion.
RECOMMEND
Federal Reserve officials "collectively release information": Be cautious about the inflation risk of tariffs, not in a hurry to cut interest rates.
10/05/2025
National Bureau of Statistics: In April 2025, the year-on-year decrease in the producer prices of industrial products at the factory was 2.7%.
10/05/2025
People's Daily Bell: It is not realistic to expect to solve problems with just one or two negotiations.
10/05/2025
